← boardnext 2026-10
PHAT
Phathom Pharmaceuticals, Inc.distress 3/10 · well-funded / low risk$11.54-1%today-36% from 52w high
Lead: eosinophilic esophagitis
Revenue
$58M
Liquidity
$181M
Runway
1.9 yrs
Shares 1y
+12%
Price & events
-18.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
+5.2%
1W
+6.3%
1M
-5.1%
3M
-14.5%
6M
+34.7%
1Y
-4.9%
2Y
-64.6%
5Y
-65.9%
All
Overview
- Market Cap
- $920.46M
- Enterprise Value
- $903.23M
- Volume
- 53.27K
- 52 Week Range
- $7.83 – $18.08
- Total Shares
- 79.76M
- Float Shares
- 64.37M
- Short %
- 15.84%
- % Held by Insiders
- 4.73%
- % Held by Institutions
- 89.58%
- RVOL
- 0.05x
- Beta
- 0.49
Pipeline stages · 1 programs
Vonoprazan
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10 Estimated 50% readout ~2026-11-15 | Phase 2 | Vonoprazan | Eosinophilic Esophagitis | — | active not recruiting |
| 2025-04-05 | Phase 1 | Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water, Vonoprazan | Healthy Volunteers | 25 | completed |
Catalyst news & presentations · 6
- 2027Guided 40%readoutPhase 2VOQUEZNA (vonoprazan) · Topline primary and secondary results anticipatedSEC 8-K
- the fourth quarter 2026Guided 70%readoutPhase 2VOQUEZNA · Topline results from Phase 2 pHalcon-EoE-201 studySEC 8-K
- 2026-07-30earningsEarningsEarnings releaseyahoo
- first patient dosedtrial initiationsecondaryPhase 2VOQUEZNA (vonoprazan) · First patient dosed in Phase 2 pHalcon EoE-201 trialSEC 8-K
- 2025-06-16fda agreementVOQUEZNA · FDA Orange Book update confirms NCE exclusivity through May 3, 2032SEC 8-K
- 2025-06-06fda agreementvonoprazan · FDA approved Citizen Petition to correct Orange Book to recognize 10-year NCE exclusivity for VOQUEZNA tablets through May 3, 2032SEC 8-K
Approved drugs (4)
- VOQUEZNAVONOPRAZAN FUMARATE2024 · Prescription
- VOQUEZNAVONOPRAZAN FUMARATE2023 · Prescription
- VOQUEZNA TRIPLE PAKAMOXICILLIN2022 · Prescription
- VOQUEZNA DUAL PAKAMOXICILLIN2022 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $24 (+105% upside) · 10 analysts
- 2026-06-17HC Wainwright & Co.Buy
- 2026-03-27BarclaysEqual-Weight → Overweight
- 2026-02-27GuggenheimBuy
- 2025-12-09BarclaysEqual-Weight
- 2025-10-31HC Wainwright & Co.Buy
- 2025-06-09HC Wainwright & Co.Buy
Competitors — eosinophilic esophagitis
Recent news
- 2026-07-21Hoa Phat advances decarbonization with third phase of rooftop solar project - SteelOrbis
- 2026-07-21‘I feel like I’m where I’m meant to be now’ - North Belfast blogger turned playwright Nuala Moore on bringing My Phat Life to Féile an Phobail - The Irish News
- 2026-07-20Millennium group discloses 4.2% Phathom (PHAT) stake in amended ownership filing - Stock Titan
- 2026-07-20Avoiding Lag: Real-Time Signals in (PHAT) Movement - Stock Traders Daily
- 2026-07-20Phathom Pharmaceuticals to announce Q2 2026 financial results - scanx.trade
- 2026-07-20Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026 - The Manila Times
- 2026-07-20Phathom Pharmaceuticals to Report Second Quarter 2026 - GlobeNewswire
- 2026-07-20Phathom Pharmaceuticals to Report Second Quarter 2026 - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.